Self-infusion of subcutaneous intravenous immunoglobulin

"Self-infusion via subcutaneous intravenous immunoglobulin (SCIG) allows patient input to design an individualized and optimal treatment plan" Duff et al (2020).

Abstract:

Immunoglobulin replacement therapy is standard of care in treatment of many primary immunodeficiency diseases. The goal of replacement therapy is to reduce infections in individuals with primary immune deficiency and improve their quality of life. Immunoglobulin replacement therapy is most often lifelong, therefore ease of administration is vital for adherence to treatment. Self-infusion via subcutaneous intravenous immunoglobulin (SCIG) allows patient input to design an individualized and optimal treatment plan. Because SCIG regimens are flexible and allow for increased autonomy, patients receiving SCIG report improved quality of life. This article summarizes the dosing, administration, and adverse event management of SCIG infusions.

Reference:

Duff C, Ballow M. Nuts and Bolts of Subcutaneous Therapy. Immunol Allergy Clin North Am. 2020;40(3):527-537. doi:10.1016/j.iac.2020.04.002

Safety IV catheter